



Research in Your Backyard: Japan

Contribution of PhRMA and EFPIA Member Companies to Japanese Society & Economy
Through Clinical Trials of Innovative Medicines

November 2016

Contents

Introduction: Who We Are	3
Pharmaceutical Industry and Society	5
Collaborating on Clinical Trials	7
R&D Spending, Trends, and Results	14
Summary: For Japanese society and patients	20

Introduction: Who We Are

We are devoted to advancing public policies that support innovative medical research, yield progress for patients today, and provide hope for the treatments and cures of tomorrow



PhRMA Japan represents U.S. based pharmaceutical companies. Our activities vary from promoting healthcare system reform to providing medical information to patients.

Mission

PhRMA Japan's mission is to promote the health of patients and contribute to the healthier lives of all people



EFPIA Japan represents R&D-based European pharmaceutical companies. We focus on patient needs in Japan, engage in discussions with key stakeholders regarding public health, and work to improve the R&D environment for pharmaceutical companies.

Mission

EFPIA Japan's mission is to enhance the health of Japanese patients by introducing innovative drugs and vaccines

PhRMA and EFPIA member companies

PhRMA	EFPIA	
AbbVie GK	Actelion Pharmaceuticals Japan Ltd.	Janssen Pharmaceutical K.K.
Amgen Astellas BioPharma K.K.	AstraZeneca K.K.	LEO Pharma K.K.
Biogen Japan Ltd.	Bayer Yakuhin, Ltd	Lundbeck Japan K. K.
Bristol-Myers Squibb K.K.	Bracco-Eisai Co., Ltd.	Merck Serono Co.,Ltd.
Celgene K.K.	Chugai Pharmaceutical Co., Ltd.	Mylan EPD G.K.
Eli Lilly Japan K.K.	CSL Behring K.K.	Nihon Servier Co.,Ltd.
Janssen Pharmaceutical K.K.	Ferring Pharmaceuticals Co., Ltd.	Nippon Boehringer Ingelheim Co ., Ltd.
MSD K.K.	Galderma (Japan) K.K.	Novartis Pharma K.K.
Mundipharma K.K.	GE Healthcare Japan Corporation	Novo Nordisk Pharma Ltd.
Pfizer Japan Inc.	GlaxoSmithKline K.K.	Sanofi K.K.
	Guerbet Japan K.K.	Shire Japan K.K.
	Ipsen Pharma SAS	UCB Japan Co. Ltd.




Pharmaceutical Industry and Society

Pharmaceutical companies contribute to society and the economy in multiple ways

Pharmaceutical companies collaborate with local clinics and hospitals to develop new drugs.

This in turn provides economic stimulus and leads to innovative new medicines with better efficacy and safety profiles.






Collaborating on Clinical Trials

Discovering and developing new medicines is a long, complex, and costly process

Developing innovative medicines takes an average of 10-15 years and 2.6B USD. Less than 12% of the candidate medicines that make it into phase I clinical trials are approved. Many promising compounds fail after pharmaceutical companies have spent substantial amounts of money on testing and clinical trials




Source: Cost of Developing a New Drug, Tufts Center for the Study of Drug Development, Tufts School of Medicine. November 2014.



What is a Clinical Trial?

Computer simulations and animal testing are not enough to determine the efficacy and safety of new drugs for people. Clinical trials are conducted in five phases with the aim of clarifying the impact of experimental drugs on humans.



Source: PhRMA




What are Therapeutic Areas?

Therapeutic areas are general categories of illnesses, including the examples below

Therapeutic Area	Example
Allergy	Allergic rhinitis, Asthma, Atopic dermatitis, etc.
Infectious disease	Influenza, Hepatitis C/B, Herpes, etc.
Hematology	Anemia, Hemophilia, etc.
Respiratory disease	COPD, Bronchiectasis, etc.
Oncology	Gastric cancer, Lung cancer, Breast cancer, etc.
Cardiology	Heart failure, Brain ischemia, Hypertension, etc.
Gastroenterology	Gastric ulcer, Reflux esophagitis, etc.
CNS	Alzheimer's disease, Depression, Epilepsy, etc.
Urology	Nocturia, Lupus nephritis, etc.
Dermatology	Acne, etc.
Ophthalmology	Age-related macular degeneration, Uveitis, etc.
Immunology	Rheumatoid arthritis, Crohn's disease, Psoriasis, etc.
Musculoskeletal disease	Osteoporosis, Lower back pain, etc.
Endocrine metabolic disease	Diabetes mellitus, Hypercholesterolemia, Hyperphosphatemia, etc.
Rare disease	Gaucher disease, Myelofibrosis, Behcet's disease, etc.

Collaborating with Japanese institutions in conducting and supporting clinical trials

Conducting clinical trials involves collaboration between pharmaceutical companies and other institutions in Japan, such as hospitals, local clinics, and contract research organizations (CRO).



Pharmaceutical Companies

Decide to conduct clinical trials and request support from CRO

CRO

Support pharmaceutical companies with the coordination of clinical trials

Hospitals / Clinics

Conduct trials performed by physicians and trained research professionals

SMO

(Site Management Organizations)

Provide additional support to hospitals and clinics during trials



Partnering with local Japanese medical institutions to conduct clinical trials expands the benefit of clinical trials to the hosting area

Conducting clinical trials for new drug development contributes to local Japanese economies and improves the quality of life for people in Japan

Providing advanced treatment

Medical facilities conducting clinical trials are able to provide advanced medical treatments to their patients in these locales

Contributing to local economy

The spending on clinical trials in Japan goes to hospitals and clinics nationwide and supports local economies

Creating jobs

Related stakeholders (local medical facilities and pharmaceutical companies) employ local staff to support clinical trials

PhRMA and EFPIA member companies conducted 825 clinical trials in 2015
to deliver innovative medicines to patients in Japan

825 (+21% since 2013)

CLINICAL TRIALS*


18,095 (+55% since 2013)

SITES**

16+

THERAPEUTIC AREAS

of clinical trial conducted



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Source: www.clinicaltrials.gov (2015 data)

*Figures do not include post marketing surveillance **Individual sites participating in multiple trials are counted multiple times



PhRMA and EFPIA member companies conduct many clinical trials across all prefectures of Japan

Prefecture not specified 147

Osaka 438
Hyogo 324
Kyoto 191
Shiga 61
Nara 67
Wakayama 66

Kinki

Tottori 43
Shimane 56
Okayama 188
Hiroshima 183
Yamaguchi 100

Chugoku

Kyushu

Fukuoka 415
Saga 75
Nagasaki 112
Kumamoto 166
Oita 93
Miyazaki 59
Kagoshima 128
Okinawa 86

Hokkaido 325

Hokkaido

Toyama 76
Ishikawa 130
Fukui 65

Hokuriku

Aomori 67
Iwate 93
Miyagi 215
Akita 57
Yamagata 53
Fukushima 86

Tohoku

Kanto Koshinetsu


Tokyo 611
Kanagawa 359
Saitama 237
Chiba 346
Ibaraki 173
Tochigi 119
Gunma 148
Yamanashi 58
Nagano 123
Niigata 124

Tokai


Aichi 390
Gifu 103
Shizuoka 241
Mie 100

Shikoku

Tokushima 79
Kagawa 107
Ehime 174
Kochi 78




Source: www.clinicaltrials.gov (2015 data)



R&D Spending, Trends, and Results

PhRMA and EFPIA member companies contribute a significant share of the research and development spending in Japan




Source: JPMA data based on company disclosures for fiscal year 2014

* 72 JPMA companies ** 19 PhRMA and EFPIA member companies participating in JPMA

Note: The figures refer only to clinical research related spending during fiscal year 2014 disclosed by JPMA member companies

Reducing the “drug lag”*

PhRMA and EFPIA member companies are planning simultaneous international drug submissions** which will allow Japanese patients to be in the first wave of access to innovative medicines



Simultaneous international submissions planned by PhRMA / EFPIA member companies

- Completed simultaneous international submissions
- Planned simultaneous international submissions
- Simultaneous international submissions is under consideration
- Simultaneous international submissions is not planned or not feasible

Source: PhRMA and EFPIA Japan joint research of 28 member companies (clinical trials conducted between April 2015 and March 2016)

“Drug lag” refers to the delay to approve a new drug in Japan such as cases where approval is delayed compared to other countries, such as the U.S. and Europe


Conducting more global simultaneous clinical trials shortens the drug lag

**Simultaneous international submission refers to the submission of a new drug application (NDA) at the similar timing (within 3 months, in this study) as other countries, such as the U.S. and Europe

Bringing innovation to Japanese patients

PhRMA and EFPIA member companies obtained approval
for 185 new drugs* in Japan over the last 9 years

Number of New Drugs Approved in Japan



● Japan Total

● PhRMA and EFPIA Member Companies

Source: PMDA website


*New drugs refer to New Molecular Entities only approved between April 2007 and March 2016 (Other approvals, such as new indications, are excluded)

Besides the approvals obtained by PhRMA and EFPIA member companies, other approvals include products licensed from global companies

Continuing investment in Japan to treat more conditions

PhRMA and EFPIA member companies obtained approval
for 373 new indications* in Japan over the last 9 years

Number of New Indications Approved in Japan



● Japan Total

● PhRMA and EFPIA Member Companies

Source: PMDA website

*New indications refer to New Molecular Entities approved between April 2007 and March 2016, as well as new indications approved for existing drugs
Besides the approvals obtained by PhRMA and EFPIA member companies, other approvals include products licensed from global companies

Summary: For Japanese society and patients

We are devoted to advancing public policies that support innovative medical research, yield progress for patients today, and provide hope for the treatments and cures of tomorrow




PhRMA and EFPIA member companies' clinical research stimulates local economies through:

- *Collaboration with local Japanese clinics and hospitals to develop new drugs*
- *Funding clinical trials to develop innovative new medicines with better efficacy and safety profiles*



PhRMA and EFPIA member companies invest heavily in clinical trials across all prefectures Japan:

- *825 (+21% since 2013) clinical trials across more than 16 therapeutic areas conducted in 2015*
- *Rapid increase in clinical trials is the result of the premium for new drug development, introduced by the Ministry of Health, Labour and Welfare in 2010*



PhRMA and EFPIA member companies make continuous efforts and investment in Japan to allow Japanese patients to be in the first wave of access to innovative medicines:

- *Spent 79B JPY in the research and development in Japan in 2014*
- *Contribute around half of the new drug approvals in Japan*



To download an electronic version of this presentation,
please go to www.efpia.jp or www.phrma-jp.org, or scan the QR code above

Appendix - Research Activity Map



Prefecture Views

Japan

825


CLINICAL TRIALS

18,095

SITES

16+

THERAPEUTIC AREAS

An orange silhouette map of Japan, showing the four main islands: Hokkaido, Honshu, Shikoku, and Kyushu, along with numerous smaller islands and archipelagos.

Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Aichi

390

CLINICAL TRIALS

973

SITES

15

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Akita

57

CLINICAL TRIALS

116

SITES

13

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Aomori

67


CLINICAL TRIALS

132

SITES

11

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Chiba

346


CLINICAL TRIALS

687

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Ehime

174


CLINICAL TRIALS

269

SITES

14

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Fukui

65

CLINICAL TRIALS

115

SITES

14+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Fukuoka

415


CLINICAL TRIALS

1,110

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Fukushima

86


CLINICAL TRIALS

204

SITES

14

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Gifu

103

CLINICAL TRIALS

215

SITES

15+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Gunma

148


CLINICAL TRIALS

291

SITES

15+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Hiroshima

183


CLINICAL TRIALS

392

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Hokkaido

325


CLINICAL TRIALS

912

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Hyogo

324


CLINICAL TRIALS

765

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Ibaraki

173


CLINICAL TRIALS

389

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Ishikawa

130


CLINICAL TRIALS

228

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Iwate

93

CLINICAL TRIALS


159

SITES

15+

THERAPEUTIC AREAS

Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others



Kagawa

107

CLINICAL TRIALS

194

SITES

14

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Kagoshima

128

CLINICAL TRIALS

233

SITES

14+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Kanagawa

359


CLINICAL TRIALS

1,013

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Kochi

78

CLINICAL TRIALS

125

SITES

13

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology


Urology

Hematology

Rare Diseases

Immunology

Others



Kumamoto

166

CLINICAL TRIALS

294

SITES

16+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Kyoto

191

CLINICAL TRIALS

415

SITES

16+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Mie

100


CLINICAL TRIALS

202

SITES

15+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Miyagi

215


CLINICAL TRIALS

394

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Miyazaki

59

CLINICAL TRIALS

108

SITES

14

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Nagano

123


CLINICAL TRIALS

260

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Nagasaki

112

CLINICAL TRIALS

227

SITES

14

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Nara

67

CLINICAL TRIALS

131

SITES

13

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Niigata

124


CLINICAL TRIALS

218

SITES

13

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Oita

93

CLINICAL TRIALS

169

SITES

13

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Okayama

188

CLINICAL TRIALS

320

SITES

15+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology


Urology

Hematology

Rare Diseases

Immunology

Others



Okinawa

86

CLINICAL TRIALS

146

SITES

11

THERAPEUTIC AREAS

Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Osaka

438


CLINICAL TRIALS

1,484

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Saga

75

CLINICAL TRIALS

123

SITES

11

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Saitama

237


CLINICAL TRIALS

652

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Shiga

61

CLINICAL TRIALS

121

SITES

13

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology


Urology

Hematology

Rare Diseases

Immunology

Others



Shimane

56

CLINICAL TRIALS

89

SITES

13

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Shizuoka

241


CLINICAL TRIALS

490

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Tochigi

119


CLINICAL TRIALS

213

SITES

14

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Tokushima

79

CLINICAL TRIALS

128

SITES

14

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Tokyo

611


CLINICAL TRIALS

2,418

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Tottori

43

CLINICAL TRIALS

73

SITES

13+

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology

Urology

Hematology

Rare Diseases

Immunology

Others

Toyama

76

CLINICAL TRIALS

149

SITES

13

THERAPEUTIC AREAS

Allergy

Cardiology

CNS

Dermatology

Endocrine Metabolic Disease

Gastroenterology

Hematology

Immunology

Infectious Disease

Musculoskeletal Disease

Oncology

Ophthalmology

Respiratory Disease

Urology

Rare Diseases

Others

Wakayama

66

CLINICAL TRIALS

114

SITES

12

THERAPEUTIC AREAS

Allergy

Infectious Disease

Cardiology

Musculoskeletal Disease

CNS

Oncology

Dermatology

Ophthalmology

Endocrine Metabolic Disease

Respiratory Disease

Gastroenterology


Urology

Hematology

Rare Diseases

Immunology

Others



Yamagata

53


CLINICAL TRIALS

110

SITES

12

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others

Yamaguchi

100

CLINICAL TRIALS

198

SITES

13

THERAPEUTIC AREAS

Allergy

Cardiology

CNS

Dermatology

Endocrine Metabolic Disease

Gastroenterology

Hematology

Immunology

Infectious Disease

Musculoskeletal Disease

Oncology

Ophthalmology

Respiratory Disease

Urology

Rare Diseases

Others

Yamanashi

58


CLINICAL TRIALS

98

SITES

16+

THERAPEUTIC AREAS



Allergy	Infectious Disease
Cardiology	Musculoskeletal Disease
CNS	Oncology
Dermatology	Ophthalmology
Endocrine Metabolic Disease	Respiratory Disease
Gastroenterology	Urology
Hematology	Rare Diseases
Immunology	Others



Therapeutic Area Views

Allergy


29

CLINICAL TRIALS

722

SITES

PHASES



Cardiology


57

CLINICAL TRIALS

2,368

SITES

PHASES



CNS


49

CLINICAL TRIALS

714

SITES

PHASES



Dermatology


7

CLINICAL TRIALS

111

SITES

PHASES



Endocrine metabolic disease


82

CLINICAL TRIALS

3,739

SITES

PHASES



Gastroenterology

8

CLINICAL TRIALS

432

SITES

PHASES



Hematology


36

CLINICAL TRIALS

219

SITES

PHASES



Immunology


81

CLINICAL TRIALS

3,163

SITES

PHASES



Infectious disease


34

CLINICAL TRIALS

490

SITES

PHASES



Musculoskeletal disease


11

CLINICAL TRIALS

213

SITES

PHASES



Oncology


331

CLINICAL TRIALS

3,354

SITES

PHASES



Ophthalmology


18

CLINICAL TRIALS

273

SITES

PHASES



Rare disease*

28

CLINICAL TRIALS


587

SITES

* Rare disease includes conditions such as:

Gaucher Disease, Myelofibrosis, and Bahcet's Disease,
which could not be categorized into other therapeutic areas

PHASES



Respiratory disease


20

CLINICAL TRIALS

1,209

SITES

PHASES



Urology


14

CLINICAL TRIALS

365

SITES

PHASES



Others

20

CLINICAL TRIALS

136

SITES

PHASES

